Comparison of Liquid to Particle Embolics in a Translational Rat Model of Hepatocellular Carcinoma: Histologic and Radiographic Responses.

Purpose: To compare the effectiveness of transarterial embolization (TAE) using a liquid embolic (LE) to TAE using a particle embolic (PE) based on radiographic and histologic response in a translational rat model of hepatocellular carcinoma (HCC).

Materials And Methods: HCC was induced in Wistar rats using diethylnitrosamine. Tumor response was determined through RECIST applied to T2-weighted MRI scans.

Distinct metabolic phenotype renders β-catenin mutant hepatocellular carcinoma susceptible to treatment-induced ischemia.

Background & Aims: Transarterial chemoembolization (TACE) is the most common treatment for hepatocellular carcinoma (HCC) worldwide; however, response rates and durability vary widely. With the growing armamentarium of therapies for HCC patients, identifying predictors of response to TACE has become increasingly important for a patient population with limited hepatic reserve. We hypothesized that a distinct metabolic phenotype associated with β-catenin pathway mutations render HCC tumors more susceptible to TACE-induced ischemia.

Human GM-CSF/IL-3 enhance tumor immune infiltration in humanized HCC patient-derived xenografts.

Background & Aims: Responses to immunotherapies in hepatocellular carcinoma (HCC) are suboptimal with no biomarkers to guide patient selection. "Humanized" mice represent promising models to address this deficiency but are limited by variable chimerism and underdeveloped myeloid compartments. We hypothesized that expression of human GM-CSF and IL-3 increases tumor immune cell infiltration, especially myeloid-derived cells, in humanized HCC patient-derived xenografts (PDXs).

The Academic Impact of Society of Interventional Radiology Foundation Grants: Report from the Society of Interventional Radiology Foundation/National Institutes of Health Task Force.

The Society of Interventional Radiology Foundation (SIR Foundation) aims to promote scientific research in Interventional Radiology by providing funding to promising investigators. Over the last 26 years, the SIRF has awarded more than 280 research grants. In 2020, the SIRF created a SIRF/NIH task force to evaluate the scientific ramifications of these funds in terms of overall productivity and research impact.

Integrated Imaging Probe and Bispecific Antibody Development Enables In Vivo Targeting of Glypican-3-Expressing Hepatocellular Carcinoma.

Glypican-3 (GPC3) is a proteoglycan with high sensitivity and specificity for hepatocellular carcinoma (HCC). We describe the integrated development and validation of a GPC3-targeting optical imaging probe and T cell-redirecting antibody (TRAB) as a theranostic strategy for the detection and treatment of HCC. A novel TRAB targeting GPC3 on HCC tumor cells and the CD3 T-cell receptor as well as a distinct GPC3-specific optical imaging probe were developed from a short peptide.